Abstract
Angiogenesis, the formation of new blood vessels from preexisting microvasculature, is a highly regulated process. Angiogenesis is controlled by both positive and negative factors thus providing several targets for drug discovery. The inhibition of angiogenesis represents a new approach to cancer therapy and several agents and approaches are in different stages of clinical development. These inhibitors were recently shown to constitute a new modality for cancer treatment. In this article, we will review angiogenesis inhibitors-related patent literature for the years 2000-2005. This review will cover specifically the discovery and development disclosures of endogenous inhibitors. The scope of this review is to give the reader a well-structured patent literature review of these agents targeting different steps of the angiogenic process. Finally, we have summarized the key attributes of the emerging endogenous angiogenesis inhibitors that make them potent antitumor agents.
Keywords: Angiogenesis, cancer, antiangiogenesis inhibitors, vascular target, angiostatin, endostatin, VEGF, receptor tyrosine kinase and kringle
Recent Patents on Anti-Cancer Drug Discovery
Title: Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Volume: 1 Issue: 2
Author(s): Mohanraj Dhanabal and Natarajan Sethuraman
Affiliation:
Keywords: Angiogenesis, cancer, antiangiogenesis inhibitors, vascular target, angiostatin, endostatin, VEGF, receptor tyrosine kinase and kringle
Abstract: Angiogenesis, the formation of new blood vessels from preexisting microvasculature, is a highly regulated process. Angiogenesis is controlled by both positive and negative factors thus providing several targets for drug discovery. The inhibition of angiogenesis represents a new approach to cancer therapy and several agents and approaches are in different stages of clinical development. These inhibitors were recently shown to constitute a new modality for cancer treatment. In this article, we will review angiogenesis inhibitors-related patent literature for the years 2000-2005. This review will cover specifically the discovery and development disclosures of endogenous inhibitors. The scope of this review is to give the reader a well-structured patent literature review of these agents targeting different steps of the angiogenic process. Finally, we have summarized the key attributes of the emerging endogenous angiogenesis inhibitors that make them potent antitumor agents.
Export Options
About this article
Cite this article as:
Dhanabal Mohanraj and Sethuraman Natarajan, Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (2) . https://dx.doi.org/10.2174/157489206777442296
DOI https://dx.doi.org/10.2174/157489206777442296 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Discovery Technologies Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine A Closer Look at α-Secretase
Current Alzheimer Research Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses
Current Cancer Drug Targets Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Lipid-Based Nanocarriers for CNS-Targeted Drug Delivery
Recent Patents on CNS Drug Discovery (Discontinued) Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design